Fulgent Genetics (FLGT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed regarding upcoming shareholder meeting.
No filing fee required for this submission.
Voting matters and shareholder proposals
Materials relate to matters requiring shareholder vote at the next meeting.
Shareholder rights and capital structure
Filing confirms compliance with SEC proxy rules and shareholder communication requirements.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fulgent Genetics
- 2026 revenue is forecast at $350M, driven by acquisitions and AI-enabled growth.FLGT
Q4 202527 Feb 2026 - Growth in diagnostics and pharma, new VA contract, and margin gains highlight strong momentum.FLGTUBS Global Healthcare Conference 20243 Feb 2026
- Q2 revenue up 5% year-over-year, with margin gains and strong cash, but regulatory risks remain.FLGTQ2 20242 Feb 2026
- Q3 revenue $71.7M, core up 9% YoY, $99M VA contract, $10.1M impairment, strong cash.FLGTQ3 202415 Jan 2026
- 2024 growth is driven by lab services, new NIPT, and industry consolidation, with strong margins.FLGTPiper Sandler 36th Annual Healthcare Conference11 Jan 2026
- Strong organic growth, innovation, and clinical milestones drive future expansion.FLGTPiper Sandler 37th Annual Healthcare Conference3 Dec 2025
- Director elections, auditor ratification, and executive pay approval headline the 2025 meeting.FLGTProxy Filing1 Dec 2025
- 2024 core revenue up 7% with margin gains; 2025 guidance targets 10% growth and strong cash.FLGTQ4 20241 Dec 2025
- Q1 2025 revenue up 14–16% to $73.5M, with strong liquidity and improved margins.FLGTQ1 202528 Nov 2025